Voyager Therapeutics Inc (NASDAQ:VYGR) CFO Jane Henderson sold 15,416 shares of Voyager Therapeutics stock in a transaction on Friday, March 16th. The shares were sold at an average price of $22.15, for a total value of $341,464.40. Following the transaction, the chief financial officer now owns 15,416 shares in the company, valued at approximately $341,464.40. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Jane Henderson also recently made the following trade(s):

How to Become a New Pot Stock Millionaire
  • On Monday, March 19th, Jane Henderson sold 17,316 shares of Voyager Therapeutics stock. The shares were sold at an average price of $22.11, for a total value of $382,856.76.

Voyager Therapeutics Inc (NASDAQ:VYGR) opened at $20.50 on Friday. Voyager Therapeutics Inc has a 52 week low of $8.10 and a 52 week high of $31.91. The company has a market capitalization of $681.98, a PE ratio of -7.68 and a beta of 2.37.

Voyager Therapeutics (NASDAQ:VYGR) last issued its earnings results on Wednesday, March 14th. The company reported ($0.40) EPS for the quarter, beating analysts’ consensus estimates of ($0.72) by $0.32. Voyager Therapeutics had a negative return on equity of 63.18% and a negative net margin of 697.03%. The firm had revenue of $6.35 million for the quarter, compared to the consensus estimate of $5.81 million. sell-side analysts forecast that Voyager Therapeutics Inc will post -2.54 earnings per share for the current fiscal year.

A number of hedge funds and other institutional investors have recently modified their holdings of VYGR. Teachers Advisors LLC grew its stake in Voyager Therapeutics by 24.7% in the second quarter. Teachers Advisors LLC now owns 25,685 shares of the company’s stock valued at $230,000 after purchasing an additional 5,081 shares in the last quarter. TIAA CREF Investment Management LLC grew its stake in Voyager Therapeutics by 11.8% in the second quarter. TIAA CREF Investment Management LLC now owns 37,295 shares of the company’s stock valued at $334,000 after purchasing an additional 3,939 shares in the last quarter. Northern Trust Corp grew its stake in Voyager Therapeutics by 26.8% in the second quarter. Northern Trust Corp now owns 133,571 shares of the company’s stock valued at $1,197,000 after purchasing an additional 28,222 shares in the last quarter. Vanguard Group Inc. grew its stake in Voyager Therapeutics by 3.2% in the second quarter. Vanguard Group Inc. now owns 430,765 shares of the company’s stock valued at $3,860,000 after purchasing an additional 13,194 shares in the last quarter. Finally, Dimensional Fund Advisors LP grew its stake in Voyager Therapeutics by 232.0% in the second quarter. Dimensional Fund Advisors LP now owns 98,128 shares of the company’s stock valued at $879,000 after purchasing an additional 68,574 shares in the last quarter. Hedge funds and other institutional investors own 80.03% of the company’s stock.

A number of research analysts have recently weighed in on the company. BidaskClub upgraded Voyager Therapeutics from a “hold” rating to a “buy” rating in a report on Saturday, February 24th. BTIG Research reiterated a “buy” rating and set a $32.00 price target on shares of Voyager Therapeutics in a report on Sunday, March 11th. Piper Jaffray Companies reiterated a “buy” rating and set a $40.00 price target on shares of Voyager Therapeutics in a report on Monday, March 12th. Wedbush downgraded Voyager Therapeutics from an “outperform” rating to a “neutral” rating and set a $29.00 price target on the stock. in a report on Monday, March 12th. Finally, Morgan Stanley lifted their price target on Voyager Therapeutics from $36.00 to $39.00 and gave the company an “overweight” rating in a report on Wednesday, February 21st. Two equities research analysts have rated the stock with a sell rating, three have issued a hold rating and nine have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $29.73.

WARNING: This news story was posted by Watch List News and is the property of of Watch List News. If you are viewing this news story on another domain, it was illegally stolen and republished in violation of US & international trademark and copyright legislation. The original version of this news story can be read at https://www.watchlistnews.com/voyager-therapeutics-inc-vygr-cfo-jane-henderson-sells-15416-shares/1959922.html.

About Voyager Therapeutics

Voyager Therapeutics, Inc is a clinical-stage gene therapy company. The Company focuses on developing treatments for patients suffering from severe diseases of the central nervous system (CNS). The Company’s pipeline consists of programs for CNS indications, including advanced Parkinson’s disease; a monogenic form of amyotrophic lateral sclerosis (ALS); Huntington’s disease; Friedreich’s ataxia; frontotemporal dementia/Alzheimer’s disease, and severe chronic pain.

Insider Buying and Selling by Quarter for Voyager Therapeutics (NASDAQ:VYGR)

Receive News & Ratings for Voyager Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.